This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
=== Pharmacokinetics === Four primary metabolic pathways of 3-HO-PCP have been identified. These include piperidine hydroxylation, N-dealkylation, O-glucuronidation, and O-sulfate-conjugation. In urine samples, the N-dealkylated-COOH metabolite was the main metabolite detected. Although it was hypothesized that 3-HO-PCP might be a metabolite of PCP in humans, there is no evidence that this is the case. 3-HO-PCP is a metabolite of 3-MeO-PCP.
Benzodiazepines developed in the former Soviet Union (e.g. phenazepam, gidazepam etc.) Benzodiazepines predominantly used only in Japan (e.g. nimetazepam, flutoprazepam etc.) 4,5-cyclised benzodiazepines (e.g. ketazolam, cloxazolam etc.), and other compounds not researched by Roche Benzodiazepines developed more recently (e.g. remimazolam, QH-ii-066, Ro48-6791 etc.) "Designer" benzodiazepines for which in vitro binding data are unavailable (e.g. flubromazolam, pyrazolam etc.) While binding or activity data are available for most of these compounds also, the assay conditions vary between sources, meaning that in many cases the values are not suitable for a direct comparison. Many older sources used animal measures of activity (i.e. sedation or anticonvulsant activity) but did not measure in vitro binding to benzodiazepine receptors. See for instance Table 2 vs Table 11 in the Chem Rev paper, Table 2 lists in vitro pIC50 values matching those below, while Table 11 has pEC50 values derived from in vivo assays in mice, which show the same activity trends but cannot be compared directly, and includes data for compounds such as diclazepam and flubromazepam which are not available in the main data set. Also note;
== Epidemiology == With the difficulty in diagnosing a TIA due to its nonspecific symptoms of neurologic dysfunction at presentation and a differential diagnosis including many mimics, the exact incidence of the disease is unclear. It was estimated to have an incidence of approximately 200,000 to 500,000 cases per year in the US in the early 2000s according to the American Heart Association. TIA incidence trends similarly to stroke, such that incidence varies with age, gender, and different race/ethnicity populations. Associated risk factors include age greater than or equal to 60, blood pressure greater than or equal to 140 systolic or 90 diastolic, and comorbid diseases, such as diabetes, hypertension, atherosclerosis, and atrial fibrillation. It is thought that approximately 15 to 30 percent of strokes have a preceding TIA episode associated.
=== 2020s === 2020: The Nigerian Academy of Science elected epidemiologist/parasitologist Ekanem Braide as its first female president. 2020: Brazilian Scientist and Researcher Jaqueline Goes de Jesus, sequenced COVID-19 genome in 12 hours. 2020: Biochemists Jennifer Doudna (American) and Emmanuelle Charpentier (French) received the Nobel Prize in Chemistry for their work on CRISPR genome editing tool. 2020: American astronomer Andrea M. Ghez received the Nobel Prize in Physics for the discovery of a supermassive compact object. 2020: German-Turkish scientist Özlem Türeci is the co-founder and chief medical officer of BioNTech. Her team developed BNT162b2 (tozinameran (INN)), commonly known as the Pfizer–BioNTech COVID-19 vaccine. 2020: British vaccinologist Sarah Gilbert leads the development and testing of a vaccine which becomes the Oxford–AstraZeneca COVID-19 vaccine. 2021: Catherine Heymans was appointed as the first female Astronomer Royal for Scotland. 2022: American chemist Carolyn R. Bertozzi received the Nobel Prize in Chemistry for her development of Bioorthogonal chemistry. 2023: Australian geomicrobiologist Jillian Banfield became the first female recipient of the van Leeuwenhoek Medal, which she received for her studies of complex microbial communities and their interaction with the environment. 2023: Hungarian American scientist Katalin Kariko receives Noble prize in Physiology or Medicine with Drew Weissman for their discoveries on nucleoside base modifications that enabled the development of effective mRNA vaccines.
After neighbors reported the crime and named Karriem as a likely suspect, Karriem and wife Bertha (35) were arrested at 2729 Clinton street. In custody, Karriem admitted to the slayings. Karriem told police: "I had to kill somebody, I could not forsake my gods". Karriem reportedly told police "The ninth hour of the twentieth day had come Sunday. It was predestined 1,500 years ago that at that hour I must make a human sacrifice to my gods. It must not be a member of the Order of Islam." Karriem claimed Smith assented to the sacrifice, telling police "At first he didn't want to be killed, but when I showed him that he would be the saviour of the world and go to heaven right away, he said all right." Press on November 21 reported Karriem was the self-described "King" of a 100-member cult. Police initially suspected Karriem might be tied to the 1929 slaying of Benny Evangelista, whom press called a cult leader. Press ran a second story on the practice of Voodoo. Karriem explained "Smith was sitting in a chair in front of the altar. My wife was time-keeper. As the hour drew near, I said, 'Smith, do you still want to be killed?' because the command ordered me not to kill anybody who didn't want to be killed. Smith nodded his head. When it was just 12 o'clock, I said, 'Smith, get up and stand on the altar.' I grabbed my dirk (an eight-inch case knife) and stabbed him like this. Smith fell off the altar and started to groan and tried to get up.
Sources: en.wikipedia.org
== Prognosis == Kwashiorkor is associated with a high risk of mortality and long-term complications. Treatment under the guidelines of the World Health Organization has proven to reduce this mortality risk and affected children tend to recover faster than children with other severe malnutrition diseases. However, physical and intellectual capabilities are not fully restored. Growth stunting and chronic disruption of microbiota are commonly observed after recovery. A high risk of death is identified by a brachial perimeter < 11 cm or by a weight-for-age threshold < −3 z-scores below the median of the WHO child growth standards. In practice, malnourished children with edema are suffering from potentially life-threatening severe malnutrition.
=== Emerging fields === Photopharmacology is an emerging approach in medicine in which drugs are activated and deactivated with light. The energy of light is used to change for shape and chemical properties of the drug, resulting in different biological activity. This is done to ultimately achieve control when and where drugs are active in a reversible manner, to prevent side effects and pollution of drugs into the environment. Epigenetic therapy may offer an alternative 'master switch' to gene therapy to introduce persistent changes to the phenotype. Aging is well-known to be measurable through epigenetic clock. Drugs may induce persistent changes. When they cause drugs to lose efficacy, it is called drug tolerance. On the other hand, they may introduce benign changes to the body. Psychoplastogen produce profound effects by regulating neuroplasticity. Psychostimulants prevent grey matter loss in ADHD patients, at therapeutic doses.
For instance, a high CSI:FingerID score of a hit should increase but never decrease the confidence that the hit is correct. Some features necessitate the existence of at least two candidates for comparison, and separate SVMs are trained for single instances. The decision values of the SVM are mapped to posterior probability estimates using Platt scaling. This comprehensive approach ensures a robust and nuanced assessment of the confidence in molecule identifications.
=== Synthesis and release === The corpus luteum produces the 6-kDa peptide hormone relaxin. Prolactin and insulin-like growth factor binding protein are two examples of the hormones and growth factors that relaxin can stimulate the secretion of. Preprorelaxin is the collective term for the signal peptide, B chain, C peptide, and A chain found in the coding area of human relaxin genes. The signal peptide is cleaved to produce prorelaxin. Prohormone convertases, such as prohormone convertase-1 and prohormone convertase-2, can convert prorelaxin to mature relaxin.
Sources: en.wikipedia.org
== Classical chiral selectors and CSPs == The intense research for development of efficient chiral selectors has resulted in the synthesis of over 1400 CSPs and over 200 CSPs have been commercialized and available in the market. The most commonly employed chiral selectors are categorized and presented in the table.
=== Dose reconstruction using biological dosimetry === Since about 1988, in addition to physical dosimetry, biological dosimetry has made it possible to reconstruct the individual dose of ionizing radiation. This is especially important for unforeseen and accidental exposures, where radiation exposures occur without physical dose monitoring. Biological markers, particularly cytogenetic markers in blood lymphocytes, are used for this purpose. Techniques for detecting radiation damage include analyzing dicentric chromosomes after acute radiation exposure. Dicentric chromosomes result from defective repair of chromosome breaks in two chromosomes, resulting in two centromeres instead of one like undamaged chromosomes. Symmetric translocations, detected through fluorescence in situ hybridization (FISH), are used after chronic or long-term exposure to radiation. The micronucleus test and the premature chromosome condensation (PCC) test are available to measure acute exposure.
=== Caenorhabditis elegans === Fic-1 is the only Fic protein present in the genetic code of C. elegans. It is primarily found in the ER nuclear envelope of adult germline cells and embryotic cells, but small amounts may be found within the cytoplasm. This extra-ER pool of FICD-1s is credited with AMPylation of core histones and eEF1-A type translation factors within the nematode. Though varying AMPylation levels did not create any noticeable effects within the nematode's behaviour or physiology, Fic-1 knockout worms were more susceptible to infection by Pseudomonas aeruginosa compared to the counterparts with active Fic-1 domains, implying a link between AMPylation of cellular targets and immune responses within nematodes.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.